Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial
Vicente E Torres, Arlene B Chapman, Olivier Devuyst, Ron T Gansevoort, Ronald D Perrone, Ann Dandurand, John Ouyang, Frank S Czerwiec, Jaime D Blais, TEMPO 4:4 Trial Investigators, Vicente E Torres, Arlene B Chapman, Olivier Devuyst, Ron T Gansevoort, Ronald D Perrone, Ann Dandurand, John Ouyang, Frank S Czerwiec, Jaime D Blais, TEMPO 4:4 Trial Investigators
Abstract
Background: In TEMPO 3:4, the vasopressin V2 receptor antagonist tolvaptan slowed total kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline relative to placebo.
Methods: TEMPO 4:4 was designed to provide an additional 2 years of data on the long-term safety and efficacy of tolvaptan in subjects completing TEMPO 3:4. The objective was to assess the disease-modifying effects of tolvaptan on TKV and eGFR end-points including change from baseline over the combined duration of TEMPO 3:4 and TEMPO 4:4, and non-inferiority of slopes during TEMPO 4:4.
Results: Of the 1445 subjects randomized to TEMPO 3:4, 871 (60.3%) enrolled in TEMPO 4:4. Percent changes in TKV from TEMPO 3:4 baseline to TEMPO 4:4 Month 24 were 29.9% and 31.6% (prior tolvaptan versus prior placebo, P = 0.38). Adjusting for baseline covariates improved the TKV treatment difference at Month 24 in TEMPO 4:4 from -1.70% to - 4.15% between the groups (P = 0.04). Slopes of TKV growth during TEMPO 4:4 were higher in early- versus delayed-treatment groups (6.16% versus 4.96% per year, P = 0.05). Analysis of secondary eGFR endpoints demonstrated a persistent effect on eGFR (3.15 mL/min/1.73 m2, P < 0.001), and non-inferiority in eGFR slopes. The safety profile on exposure to tolvaptan in TEMPO 4:4 was similar to that in TEMPO 3:4.
Conclusions: The results of TEMPO 4:4 support a sustained disease-modifying effect of tolvaptan on eGFR. The lack of a sustained treatment difference on TKV may be accounted for by limitations of the trial design, including loss of randomization and baseline imbalances ensuing TEMPO 3:4. The safety profile was similar to that observed in TEMPO 3:4.
Trial registration: ClinicalTrials.gov NCT00428948.
© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA.
Figures
References
- Ong AC, Devuyst O, Knebelmann B. et al. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 2015; 385: 1993–2002
- Chapman AB, Devuyst O, Eckardt KU. et al. Autosomal dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2015; 88: 17–27
- Grantham JJ, Mulamalla S, Swenson-Fields KI.. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2011; 7: 556–566
- Gattone VH, Wang X, Harris PC. et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9: 1323–1326
- Torres VE, Wang X, Qian Q. et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10: 363–364
- Wang X, Wu Y, Ward CJ. et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008; 19: 102–108
- Torres VE, Harris PC.. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 2014; 25: 18–32
- Torres VE, Chapman AB, Devuyst O. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407–2418
- Non-Inferiority Clinical Trials to Establish Effectiveness: Guidance for Industry, Food and Drug Administration, Division of Drug Information, Office of Communications, Center for Drug Evaluation and Research
- Gansevoort RT, Meijer E, Chapman AB. et al. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrol Dial Transplant 2016; 31: 1887–1894
- Gansevoort R, van Gastel M, Chapman A. et al. Copeptin, a surrogate for Vasopressin, predicts disease progression and Tolvaptan treatment efficacy in ADPKD. Results of the TEMPO 3:4 trial. J Am Soc Nephrol 2016; 27: 34A
- Irazabal MV, Blais JD, Perrone RP. et al. Prognostic enrichment design in clinical trials for ADPKD: The TEMPO 3:4 clinical trial. Kidney Int Rep 2016; 1: 213–220
- Cornec-Le Gall E. Can we further enrich ADPKD clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. J Am Soc Nephrol 2016; 27: 766A.
- Torres VE, Higashihara E, Devuyst O. et al. Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol 2016; 11: 803–811
- Watkins PB, Lewis JH, Kaplowitz N. et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf 2015; 38: 1103–13
- Bhattaram VA, Siddiqui O, Kapcala LP. et al. Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease. Am Assoc Pharm Sci J 2009; 11: 456–464
- Irazabal MV, Torres VE, Hogan MC. et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 2011; 80: 295–301
- Boertien WE, Meijer E, de Jong PE, et al.Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function. Am J Kidney Dis 2015; 65: 833–841
- Reif GA, Yamaguchi T, Nivens E. et al. Tolvaptan inhibits ERK-dependent cell proliferation, Cl(-) secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol 2011; 301: F1005–F1013
- Grantham JJ, Torres VE, Chapman AB. et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122–2130
- Chapman AB, Bost JE, Torres VE. et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2012; 7: 479–486
- Bankir L, Bouby N, Ritz E.. Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol 2013; 9: 223–239
Source: PubMed